Auxilium Pharmaceuticals Reports Mixed Results (AUXL)

Malvern, Pennsylvania-based biopharmaceutical company 3Auxilium Pharmaceuticals, Inc. AUXL on Thursday morning released financial results that failed to meet Wall Street earnings expectations, while beating revenue estimates. Auxilium Pharmaceuticals, Inc reported that its 4th quarter net loss widened to $16.4 million, or 34 cents per share, compared to a net loss of $11.9 million, or 25 cents per share, a year earlier. Auxilium Pharmaceuticals, Inc reported revenue of $61.8 million, up 29% from $48.03 million a year earlier. A poll of analysts conducted by Thomson Reuters showed an average Wall Street estimate of an expected loss of 30 cents per share, on revenue of $60.3 million. Auxilium Pharmaceuticals, Inc. (AUXL) ended the previous trading session at $23.41 per share. Analysts covering the company's stock have a consensus price target of $27.60 per share. Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists. Read more from Benzinga's Company news.